Immune checkpoint inhibitors (ICIs), which block regulatory proteins like PD-1, PD-L1, or CTLA-4 to enhance T-cell activation and enable immune responses against cancer, are significantly influenced by circadian rhythms (114). The gene discussed is CTLA4; the disease is cancer.